CVC  Regeneron Ventures

https://regeneronventures.com/





     Office Locations:

777 Old Saw Mill River Road
Tarrytown, NY 10591
Phone: 914-847-7000

 

Stages:

  • Early


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Regeneron Ventures announced its formation as a venture capital fund (April 2024) focused on promising biopharmaceutical, health care and health technology companies. The fund's general partner will be independently managed by former Regeneron executives Jay S. Markowitz, M.D., and Michael Aberman, M.D., who together will lead investment strategy of the fund. Regeneron Pharmaceuticals, Inc. is the fund's exclusive limited partner and has committed $100 million annually for five years. The fund's interest is skewed towards biotechnology, devices, tools, and enabling technologies.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Jay Markowitz Partner
    Michael Aberman Partner

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      12/11/2024


      Tasca Therapeutics


      MA


      $52,000,000


      Series A


      09/04/2024


      ArsenalBio


      CA


      $325,000,000


      Series C


     

    Portfolio companies include:

     

    Recent News: